1. Home
  2. XPRO vs EVO Comparison

XPRO vs EVO Comparison

Compare XPRO & EVO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • XPRO
  • EVO
  • Stock Information
  • Founded
  • XPRO 1938
  • EVO 1993
  • Country
  • XPRO United States
  • EVO Germany
  • Employees
  • XPRO N/A
  • EVO N/A
  • Industry
  • XPRO Oilfield Services/Equipment
  • EVO Biotechnology: Pharmaceutical Preparations
  • Sector
  • XPRO Energy
  • EVO Health Care
  • Exchange
  • XPRO Nasdaq
  • EVO Nasdaq
  • Market Cap
  • XPRO 1.5B
  • EVO 1.4B
  • IPO Year
  • XPRO 2013
  • EVO 2021
  • Fundamental
  • Price
  • XPRO $13.16
  • EVO $3.31
  • Analyst Decision
  • XPRO Buy
  • EVO Strong Buy
  • Analyst Count
  • XPRO 4
  • EVO 1
  • Target Price
  • XPRO $14.00
  • EVO $7.00
  • AVG Volume (30 Days)
  • XPRO 1.2M
  • EVO 54.5K
  • Earning Date
  • XPRO 10-23-2025
  • EVO 11-05-2025
  • Dividend Yield
  • XPRO N/A
  • EVO N/A
  • EPS Growth
  • XPRO 313.92
  • EVO N/A
  • EPS
  • XPRO 0.59
  • EVO N/A
  • Revenue
  • XPRO $1,661,811,000.00
  • EVO $887,396,457.00
  • Revenue This Year
  • XPRO N/A
  • EVO N/A
  • Revenue Next Year
  • XPRO $2.88
  • EVO $10.78
  • P/E Ratio
  • XPRO $23.39
  • EVO N/A
  • Revenue Growth
  • XPRO N/A
  • EVO N/A
  • 52 Week Low
  • XPRO $6.70
  • EVO $2.84
  • 52 Week High
  • XPRO $14.97
  • EVO $5.64
  • Technical
  • Relative Strength Index (RSI)
  • XPRO 50.56
  • EVO 28.61
  • Support Level
  • XPRO $13.39
  • EVO $3.30
  • Resistance Level
  • XPRO $14.53
  • EVO $4.09
  • Average True Range (ATR)
  • XPRO 0.60
  • EVO 0.09
  • MACD
  • XPRO -0.04
  • EVO -0.08
  • Stochastic Oscillator
  • XPRO 36.04
  • EVO 2.06

About XPRO Expro Group Holdings N.V.

Expro Group Holdings NV offers products and services that span the well life cycle, including well construction, well flow management, well intervention and integrity, and subsea well access. It maintains operations around the world and specializes in offshore production solutions. It also provides production optimization for both onshore and offshore applications. The company has four operating segments: North and Latin America (NLA); Europe and Sub-Saharan Africa (ESSA); Middle East and North Africa (MENA), and Asia-Pacific (APAC). The majority of its revenue is derived from North and Latin America (NLA) segment.

About EVO Evotec SE

Evotec is a drug discovery partnership firm providing solutions to pharmaceutical and biotechnology companies, academic institutions, foundations, and nonprofit organizations. The company offers services in a variety of therapeutic areas, including central nervous system disorders, diabetes, inflammation, oncology, infectious diseases, and women's health. The shared R&D segment, roughly 80% of sales, provides drug discovery and manufacturing services on a typical fee-for-service basis and integrated drug discovery collaborations based on its proprietary, internally developed assets. The Just-Evotec Biologics segment, about 20% of sales, offers CDMO services for biologics. As of 2023, the company has over 5,000 employees and 18 production sites mainly in Europe and the United States.

Share on Social Networks: